Transformative biopreservation
designed to change the world

Discover Our Technology

Upkara is revolutionizing the way biomedical industries tackle cold-chain challenges, not by mitigating them, but by eliminating them. Our innovative biopreservation technology improves access to therapeutics and research tools by enabling ambient temperature storage and transportation. Imagine what you can accomplish when you break free from the cold chain.

OUR AREAS OF IMPACT

Say goodbye to
cold chain restrictions

Learn more about how our innovative technology stabilizes biomolecules without freezing and the cost and time savings it delivers.

discover our technology
SAVINGS

Technology designed to save your business time and money

Whether your company is designing the next generation of research tools or pharmaceuticals, our no-freeze biopreservation technology saves both time and money–all while reducing waste.

Money

Eliminates expenses related to cold-chain storage and transport

Environment

Fewer carbon emissions from cold storage

Time

Significantly faster stabilization than lyophilization

Waste 

Increased manufactured product yield and reduced product loss due to temperature excursions

Applications

Our technology has an impact across several industries

  • Research and Development
  • Product testing
  • Environmental screening
  • Biobanking
  • Diagnostics
  • Pharmaceuticals
Get Started

Why it matters

0 Billion
Lost annually due to cold chain failures
0 Billion
In cold storage costs for a major research university annually
0 Million
Spent annually on cold pharmaceutical storage
0 Hour
For preservation with Upkara’s technology vs. 12-72 hours with lyophiization

Frequently Asked Questions

Our biopreservation technology stabilizes biomolecules without freezing, protecting them from temperature-mediated degradation. This means products can be stored and distributed safely at ambient temperatures, decreasing the need for cold storage and transportation.

Although we have not yet explored every possible application of our technology, we have demonstrated the ability to stabilize antibodies, enzymes, small molecules, and mRNA.
We fully anticipate that our technology can stabilize the same products that lyophilization is currently used for. There is a possibility our technology may stabilize molecules that cannot be lyophilized due to damage caused during the freezing step associated with lyophilization.

We are exploring ways our technology can be used to aid the development and distribution of human health products. Just 10% of healthcare facilities in the world’s poorest countries have access to reliable electricity.
Being able to produce and transport life-saving diagnostic reagents, therapeutics, and vaccines without the need for cold storage would drastically improve global access.